NCT07471789: Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Sponsor: Gyala Therapeutics. Phase: PHASE1. Conditions: Acute Myeloblastic Leukaemia, Leukemia, T-Cell